Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).

Q1 2026 Highlights

• Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
• FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
• Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.
• ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed
  1
  .
• TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)
  2
  for Pixclara®
  3
  . Marketing Authorization Application (MAA) filed in Europe
  4
  for Pixlumi®
  3
  .
• TLX591-Px
  5
  : NDA accepted in China by the National Medical Products Administration (NMPA)
  6
  .
  
  

Q1 2026 Revenue (Unaudited)

Revenue (US$M)	Q1 2026	Q1 2025	Variation	Q4 2025	Variation
Group revenue	230	186	24%	208	11%
Precision Medicine revenue 7	186	151	23%	161	16%
TMS third-party revenue 8	44	34	29%	44	—%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA

imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.”

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q1 2026 highlights include:

• TLX591-Tx (lutetium (
  177
  Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed
  1
  . No adverse drug-drug interactions were observed in TLX591-Tx combinations, demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC
  10
  , including ARPIs
  11
  (enzalutamide or abiraterone) and docetaxel. Telix has commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for enrollment in Australia, New Zealand and Canada, with site activation underway in preparation to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have already been granted.
• TLX250-Tx (lutetium (
  177
  Lu) girentuximab tetraxetan): Telix has opened its first clinical site and is recruiting patients for Part 1 of LUTEON
  12
  , a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC
  13
  . Trial recruitment will initially focus ex-U.S.
• TLX101-Tx (
  131
  I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma
  14
  . The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium.
• TLX090-Tx (
  153
  Sm-DOTMP): Telix continues to dose patients in SOLACE
  15
  , a Phase 1 study of a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers. The study was expanded this quarter to include additional U.S. sites to accelerate recruitment.
• TLX597-Tx (
  177
  Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a "next generation" PSMA-targeting prostate cancer therapy candidate being developed to facilitate patient access in select geographies, where routine clinical availability to approved therapies is limited or not available. Early clinical data suggests a favorable asset biodistribution with limited uptake in healthy organs of concern (e.g., salivary glands, kidneys) relative to available
  177
  Lu-PSMA therapies. Interim data from OPTIMAL-PSMA
  16
  , an investigator-led, randomized, dose intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate Cancer Symposium in April 2026.
  
  

Precision Medicine Business Unit

PSMA imaging portfolio:

• Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries globally, which includes 16 countries in Europe. This growing international presence enhances access to PSMA-PET/CT imaging
  17
  while establishing a scalable commercial and operational platform to support future product launches, including follow-on therapeutic products.
• Telix's broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for Drug Evaluation as part of the NDA submission
  18
  .
  
  

TLX101-Px, (Floretyrosine F 18 or

F-FET):

• Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.
• Telix has submitted a MAA in Europe covering commercially significant markets, seeking to expand patient access to advanced brain imaging.
  
  

Zircaix®

(TLX250-Px,

89

Zr-DFO-girentuximab):

• Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required, targeting a H1 2026 submission.
  
  

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May 11, 2026, as part of its Board renewal process

. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board believes Mr. Gill's appointment will enhance the Board’s capability, with extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies.

FY 2026 guidance

• Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million
  20
  .
• Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
• Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to US$240 million, subject to achieving ongoing global commercial milestones.
  
  

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix (kit for the preparation of gallium-68 (

Ga) gozetotide injection) has been approved by the FDA , and in multiple markets globally. Gozellix (kit for the preparation of gallium-68 ( Ga) gozetotide injection) has been approved by the FDA . No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.